Abstract
Malignant melanomas are known for their remarkable morphological variation and aberrant immunophenotype with loss of lineage-specific markers, especially in recurrences and metastases. Hot spot mutations in BRAF, NRAS, GNAQ, and GNA11 and mutations in KIT are oncogenic events in melanomas. Therefore, genotyping can be a useful ancillary diagnostic tool. We present one case each of recurrent and metastatic melanoma, both showing histological and immunohistochemical features of solitary fibrous tumor (SFT). Mutational analysis detected BRAF and NRAS mutations in the primary and secondary lesions, respectively. This result confirmed the diagnosis of recurrent/metastastic melanoma.
Similar content being viewed by others
References
Banerjee SS, Harris M (2000) Morphological and immunophenotypic variations in malignant melanoma. Histopathology 36(5):387–402
Breza TS, Magro CM (2005) CD34 expression in primary cutaneous malignant melanoma: apropos of a case and review of the aberrant melanoma phenotype. J Cutan Pathol 32(10):685–689
Lee H, Torres FX, McLean SA, Chen R, Lee MW (2011) Immunophenotypic heterogeneity of primary sinonasal melanoma with aberrant expression of neuroendocrine markers and calponin. Appl Immunohistochem Mol Morphol 19(1):48–53
Magro CM, Crowson AN, Mihm MC (2006) Unusual variants of malignant melanoma. Mod Pathol 19:S41–S70
Plaza JA, Suster D, Perez-Montiel D (2007) Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique. Appl Immunohistochem Mol Morphol 15(4):421–425
Solus JF, Kraft S (2013) Ras, Raf, and MAP kinase in melanoma. Adv Anat Pathol 20(4):217–226
Miller DD, Emley A, Yang S, Richards JE, Lee JE, Deng A, Hoang MP, Mahalingam M (2012) Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal. Mod Pathol 25(4):505–515
Whiteman DC, Pavan WJ, Bastian BC (2011) The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 24(5):879–897
Dahl C, Guldberg P (2007) The genome and epigenome of malignant melanoma. APMIS 115(10):1161–1176
Kusters-Vandevelde HV, Klaasen A, Küsters B et al (2010) Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 119(3):317–323
Rikhof B, van Doorn J, Suurmeijer AJ et al (2009) Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol 20(9):1582–1588
Barnett SL, Wells MJ, Mickey B, Hatanpaa KJ (2011) Perineural extension of cutaneous desmoplastic melanoma mimicking an intracranial malignant peripheral nerve sheath tumor. Case report. J Neurosurg 115(2):273–277
Idriss MH, De Jesús G, McClain SA, Gottlieb GJ (2013) Melanoma masquerading as xanthogranuloma: a diagnostic pitfall. Am J Dermatopathol 35(3):e41–e44
Kontozis L, Sotoriou M et al (2011) Isolated right atrial metastasis of malignant melanoma mimicking a myxoma. Hell J Cardiol 52(3):281–284
Lehmer LM, Raqsdale BD, Frost MV, Ferguson KL (2011) Large neglected ulcerated melanoma mimicking extramedullary plasmacytoma. Am J Dermatopathol 33(8):e94–e98
Ordonez NG (2013) Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update. Hum Pathol. doi:10.1016/j.humpath.2013.02.007
Schneider M, Höltje J, Kehler U, Hartmann V, Holl-Ullrich K, Oechel K, Urban PP (2013) Malignant perivascular melanoma mimicking primary central nervous system vasculitis. J Neurol 260(2):680–684
Sidiropoulos M, Syro LV, Rotondo F et al (2013) Melanoma of the sellar region mimicking pituitary adenoma. Neuropathology 33(2):175–178
Tsuchihashi H, Ito A, Tsukada H, Hasegawa H, Naitoh H, Hanasawa K, Okada K (2011) A case of amelanotic anorectal malignant melanoma mimicking gastrointestinal stromal tumor. Gan To Kagaku Ryoho 38(13):2659–2662
Hoang MP, Selim MP, Bentley RC, Burchette JL, Shea CR (2001) CD34 expression in desmoplastic melanoma. J Cutan Pathol 28(10):508–512
Zelger BG, Steiner H, Wambacher B, Zelger B (1997) Malignant melanomas simulating various types of soft tissue tumors. Dermatol Surg 23(11):1047–1054
Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ, Luthra R (2013) Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn 15(2):220–226
Dearden S, Stevens J, Wu JL, Blowers D (2013) Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 24(9):2371–2376
Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK (2013) Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 37(5):685–698
Ohashi K, Sequist LV, Arcila ME et al (2013) Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res 19(9):2584–2591
Sinicrope FA, Smyrk TC, Tougeron D et al (2013) Mutation-specific antibody detects mutant BRAF protein expression in human colon carcinomas. Cancer 119(15):2765–2770
Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS (2011) Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Gene Chromosome Cancer 50(5):307–312
Robinson DR, Wu YM, Kalyana-Sundaram S et al (2013) Identification of recurrent NAB2–STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 45(2):180–185
Blokx WA, Lesterhuis WJ, Andriessen MP, Verdijk MA, Punt CJ, Ligtenberg MJ (2007) CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma. Am J Surg Pathol 31(4):637–641
Kusters-Vandevelde HV, Keunen JE, Wesseling P, Verdijk MA, Ligtenberg MJ, Blokx WA (2008) Occurrence of ocular melanoma thirteen years after skin melanoma: two separate primaries or metastatic disease? A case solved with NRAS and CDKN2A (INK4A-ARF) mutational analysis. Virchows Arch 452(3):331–336
Box NF, Terzian T (2008) The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res 21(5):525–533
Colombino M, Capone M, Lissia A et al (2012) BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30(20):2522–2529
Gast A, Scherer D, Chen B et al (2010) Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Gene Chromosome Canc 49(8):733–745
Giglia-Mari G, Sarasin A (2003) TP53 mutations in human skin cancers. Hum Mutat 21(3):217–228
Piccinin S, Doglioni C, Maestro R, Vukosavljevic T, Gasparotto D, D’Orazi C, Boiocchi M (1997) p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 74(1):26–30
Soto JL, Carbrera CM, Serrano S, López-NEvot MA (2005) Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B. BMC Cancer 5:36
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bekers, E.M., van Engen-van Grunsven, A.C.H., Groenen, P.J.T.A. et al. Metastatic melanoma mimicking solitary fibrous tumor: report of two cases. Virchows Arch 464, 247–251 (2014). https://doi.org/10.1007/s00428-014-1542-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-014-1542-5